Dopamine transporter deficiency syndrome: phenotypic spectrum from infancy to adulthood
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Dopamine transporter deficiency syndrome due to SLC6A3 mutations is the first inherited dopamine 'transportopathy' to be described, with a classical presentation of early infantile-onset progressive parkinsonism dystonia. In this study we have identified a new cohort of patients with dopamine transporter deficiency syndrome, including, most significantly, atypical presentation later in childhood with a milder disease course. We report the detailed clinical features, molecular genetic findings and in vitro functional investigations undertaken for adult and paediatric cases. Patients presenting with parkinsonism dystonia or a neurotransmitter profile characteristic of dopamine transporter deficiency syndrome were recruited for study. SLC6A3 mutational analysis was undertaken in all patients. The functional consequences of missense variants on the dopamine transporter were evaluated by determining the effect of mutant dopamine transporter on dopamine uptake, protein expression and amphetamine-mediated dopamine efflux using an in vitro cellular heterologous expression system. We identified eight new patients from five unrelated families with dopamine transporter deficiency syndrome. The median age at diagnosis was 13 years (range 1.5-34 years). Most significantly, the case series included three adolescent males with atypical dopamine transporter deficiency syndrome of juvenile onset (outside infancy) and progressive parkinsonism dystonia. The other five patients in the cohort presented with classical infantile-onset parkinsonism dystonia, with one surviving into adulthood (currently aged 34 years) and labelled as having 'juvenile parkinsonism'. All eight patients harboured homozygous or compound heterozygous mutations in SLC6A3, of which the majority are previously unreported variants. In vitro studies of mutant dopamine transporter demonstrated multifaceted loss of dopamine transporter function. Impaired dopamine uptake was universally present, and more severely impacted in dopamine transporter mutants causing infantile-onset rather than juvenile-onset disease. Dopamine transporter mutants also showed diminished dopamine binding affinity, reduced cell surface transporter, loss of post-translational dopamine transporter glycosylation and failure of amphetamine-mediated dopamine efflux. Our data series expands the clinical phenotypic continuum of dopamine transporter deficiency syndrome and indicates that there is a phenotypic spectrum from infancy (early onset, rapidly progressive disease) to childhood/adolescence and adulthood (later onset, slower disease progression). Genotype-phenotype analysis in this cohort suggests that higher residual dopamine transporter activity is likely to contribute to postponing disease presentation in these later-onset adult cases. Dopamine transporter deficiency syndrome remains under-recognized and our data highlights that dopamine transporter deficiency syndrome should be considered as a differential diagnosis for both infantile- and juvenile-onset movement disorders, including cerebral palsy and juvenile parkinsonism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neurobiologic processes in drug reward and addiction
Adinoff, B. (2004) · Harvard Review of Psychiatry · doi:10.1080/10673220490910844 · Cited by 546 · cited 2×
“Dopamine dyshomeostasis is associated with several neurological and neuropsychiatric conditions including Parkinson’s disease, depression, schizophrenia, attention deficit hyperactivity disorder, autism and drug addiction (Carlsson, 1987; Greengard, 2001; Adinoff, 2004; Mehler-Wex et al., 2006; Mazei-Robison et al., 2…”
BackgroundHaack, T. B., Hogarth, P., Kruer, M. C., Gregory, A., Wieland, T., Schwarzmayr, T., Graf, E., Sanford, L., Meyer, E., Kara, E., et al. (2012) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2012.10.019 · Cited by 360 · cited 2×
“…storage disorders) (Garcı́a-Cazorla et al., 2011) and adolescents/ adults (parkin, DJ1 and PINK1-related Parkinson’s disease, PLA2G6-associated neurodegeneration, Kufor-Rakeb disease and beta-propeller protein-associated neurodegeneration syndrome) (Schneider and Bhatia, 2010; Haack et al., 2012).”
Self-citation
Cited by
Marras, C., Lang, A., van de Warrenburg, B. P., Sue, C. M., Tabrizi, S. J., Bertram, L., Mercimek‐Mahmutoglu, S., Ebrahimi‐Fakhari, D., Warner, T. T., Durr, A., et al. (2016) · Movement Disorders · doi:10.1002/mds.26527 · Cited by 285
Monoamine neurotransmitter disorders—clinical advances and future perspectives
Ng, J., Papandreou, A., Heales, S. J., & Kurian, M. A. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.172 · Cited by 281
Self-citationAsjad, H. M. M., Kasture, A., El-Kasaby, A., Sackel, M., Hummel, T., Freissmuth, M., & Sucic, S. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.797092 · Cited by 53
“The disease is marked by a hyperkinetic movement disorder, which progresses into parkinsonism (7).”
SLC6 Transporter Folding Diseases and Pharmacochaperoning
Freissmuth, M., Stockner, T., & Sucic, S. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_71 · Cited by 42
A review of psychiatric co-morbidity described in genetic and immune mediated movement disorders
Peall, K. J., Lorentzos, M. S., Heyman, I., Tijssen, M. A. J., Owen, M. J., Dale, R. C., & Kurian, M. A. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.05.014 · Cited by 14
“Dopamine Transporter (DAT) Deficiency Syndrome Several larger case series have identified early evidence of irritability with 6/11 affected in the initial cohort and 3/8 in a more recent study.[67] Genetic association and linkage studies have also suggested a role for DAT in neurodevelopmental disorders, with the SLC6…”
BackgroundSelf-citation
Metadata
- Authors
- Ng, J., Zhen, J., Meyer, E., Erreger, K., Li, Y., Kakar, N., Ahmad, J., Thiele, H., Kubisch, C., Rider, N. L., Holmes Morton, D., Strauss, K. A., Puffenberger, E. G., D’Agnano, D., Anikster, Y., Carducci, C., Hyland, K., Rotstein, M., Leuzzi, V., Borck, G., Reith, M. E. A., & Kurian, M. A.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-03-10
- Volume
- 137
- Issue
- 4
- Pages
- 1107-1119
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2001257914
- Cited by
- 157
- References
- 2
- FWCI
- 9.89
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.